Xeris Pharmaceuticals | XERS - Selling And Administration Expenses


Xeris Pharmaceuticals reported $53.14M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Celltrion KRW 9.32B 3.39B Mar/2026
Cspc Pharmaceutical CNY 1.87B 95.62M Dec/2025
Deva Holding AS TRY 462.26M 48.18M Sep/2023
Dianthus Therapeutics USD 12.47M 5.89M Mar/2026
Divis Laboratories Ltd INR 3.4B 10M Jun/2025
Eli Lilly USD 3.43B 496M Jun/2026
Kangmei Pharma CNY 237.06M 37.35M Mar/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Laboratorios Farma EUR 35.32M 2.75M Jun/2025
Malin Corporation EUR 1.1M 400K Dec/2024
Medical Developments International AUD 2.84M 4.19M Dec/2025
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Neuren Pharmaceuticals AUD 3.74M 2.5M Dec/2025
Organigram Holdings CAD 22.01M 14.28M Mar/2026
Ovoca Bio EUR 617K 15K Dec/2025
Pacira USD 91.81M 7.93M Jun/2026
Perrigo USD 3.28B 3.02B Jun/2026
Pharma Mar EUR 17.12M 1.82M Jun/2026
Qiagen NV USD 142.33M 60K Jun/2026
Sartorius EUR 221.3M 0 Jun/2026
Sino Biopharmaceutical CNY 7.54B 2.23B Jun/2025
Supernus Pharmaceuticals USD 133.64M 15.41M Jun/2026
Tilray USD 24.85M 1.7M Sep/2025
Zealand Pharma A/S 104M 12.19M Mar/2026
Zz Pientze Pharmaceu CNY 214.31M 42.4M Mar/2026